Rayner launches T-flex lens

Article

Rayner Intraocular Lenses Limited has globally launched its T-flex Aspheric toric IOL.

Rayner Intraocular Lenses Limited has globally launched its T-flex Aspheric toric IOL.

The aspheric optics are aberration-neutral for increased contrast sensitivity and depth of field and the T-flex Aspheric IOL is designed to deliver uniform refractive power from the centre of the optic to the edge, for optimal visual outcomes.At the same time, Rayner has also extended the T-flex Aspheric standard range which will now encompass +1.0D to +6.0D in 0.5D increments as opposed to the original 1.0D increments.

“Within the industry, Rayner has the most extensive range of IOLs for astigmatic correction with the T-flex Aspheric, M-flex T and Sulcoflex Toric ranges. T-flex is a further and significant enhancement of our toric IOL product offering to ophthalmic surgeons worldwide and one that helps us keep ahead of the game in this important segment of the IOL market,” says Donald Munro, managing director and chairman of Rayner Intraocular Lenses Limited.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.